Lantheus Holdings, Inc. $LNTH is Reinhart Partners LLC.’s 10th Largest Position

Reinhart Partners LLC. lifted its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 15.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,562,576 shares of the medical equipment provider’s stock after acquiring an additional 214,820 shares during the quarter. Lantheus accounts for approximately 3.1% of Reinhart Partners LLC.’s investment portfolio, making the stock its 10th largest holding. Reinhart Partners LLC. owned approximately 2.36% of Lantheus worth $103,990,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC increased its position in Lantheus by 190.2% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock valued at $87,000 after purchasing an additional 698 shares during the period. First Trust Advisors LP boosted its stake in shares of Lantheus by 37.4% during the second quarter. First Trust Advisors LP now owns 69,805 shares of the medical equipment provider’s stock valued at $5,714,000 after purchasing an additional 19,008 shares in the last quarter. Baird Financial Group Inc. boosted its stake in shares of Lantheus by 22.6% during the second quarter. Baird Financial Group Inc. now owns 2,715 shares of the medical equipment provider’s stock valued at $222,000 after purchasing an additional 500 shares in the last quarter. Daiwa Securities Group Inc. boosted its stake in shares of Lantheus by 88.1% during the second quarter. Daiwa Securities Group Inc. now owns 3,396 shares of the medical equipment provider’s stock valued at $278,000 after purchasing an additional 1,591 shares in the last quarter. Finally, Osterweis Capital Management Inc. bought a new position in shares of Lantheus during the second quarter valued at approximately $36,000. 99.06% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

LNTH has been the topic of a number of recent research reports. Wall Street Zen downgraded shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Truist Financial reiterated a “buy” rating and set a $115.00 price objective (up from $98.00) on shares of Lantheus in a research note on Monday, May 11th. JonesTrading downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, February 27th. Weiss Ratings reiterated a “hold (c)” rating on shares of Lantheus in a research note on Tuesday, May 26th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $110.00 price objective on shares of Lantheus in a research note on Tuesday, March 17th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, Lantheus presently has a consensus rating of “Moderate Buy” and an average price target of $101.86.

Lantheus Stock Performance

LNTH stock opened at $96.30 on Wednesday. The firm has a market cap of $6.27 billion, a price-to-earnings ratio of 23.20 and a beta of -0.03. The firm has a 50-day simple moving average of $86.04 and a two-hundred day simple moving average of $73.80. Lantheus Holdings, Inc. has a one year low of $47.25 and a one year high of $103.89. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.64 and a current ratio of 2.83.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, beating the consensus estimate of $1.25 by $0.21. The business had revenue of $377.33 million during the quarter, compared to analyst estimates of $354.48 million. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The company’s quarterly revenue was up 1.2% on a year-over-year basis. During the same period in the prior year, the firm posted $1.53 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, equities analysts forecast that Lantheus Holdings, Inc. will post 4.41 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.